The gold standard treatment for patients with AVD is surgical replacement of the aortic valve with either mechanical or fixed tissue prostheses. These implants have a limited lifespan and are associated with serious adverse events. Patient autologous tissue engineered heart valves (TEHVs) offer a solution. Vital to the development of a TEHV is determining a source of donor tissue(s) that most closely mimics the native valve tissue. In pursuit of determining an alternative cell source for patient autologous TEHVs we compared a number of phenotypic and genotypic characteristics of atrial fibroblasts, dermal fibroblasts and differentiated bone marrow-derived progenitor cells (BMCs) and made a comparison to valvular interstitial cells (VICS). We demonstrate that while VICs share some phenotypic similarities with fibroblasts and BMCs, they also possess unique characteristics and demonstrate differential mRNA expression of key regulatory pathways that may influence their phenotype. / October 2016
| Identifer | oai:union.ndltd.org:MANITOBA/oai:mspace.lib.umanitoba.ca:1993/31804 |
| Date | 19 September 2016 |
| Creators | Ambrose, Emma |
| Contributors | Dixon, Ian (Physiology and Pathophysiology) Cattini, Peter (Physiology and Pathophysiology) Halayko, Andrew (Physiology and Pathophysiology), Wigle, Jeff (Biochemistry and Medical Genetics) |
| Source Sets | University of Manitoba Canada |
| Detected Language | English |
Page generated in 0.0017 seconds